NASDAQ:GOSS Gossamer Bio (GOSS) Stock Price, News & Analysis $0.70 +0.03 (+4.51%) (As of 11/22/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Gossamer Bio Stock (NASDAQ:GOSS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Gossamer Bio alerts:Sign Up Key Stats Today's Range$0.67▼$0.7150-Day Range$0.66▼$1.0752-Week Range$0.50▼$1.60Volume1.79 million shsAverage Volume903,813 shsMarket Capitalization$157.63 millionP/E RatioN/ADividend YieldN/APrice Target$9.20Consensus RatingBuy Company OverviewGossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.Read More… A “Thank You Gift” From Pres. Trump - Genius (Ad)Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…Get Your Free Gold Guide Gossamer Bio Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks84th Percentile Overall ScoreGOSS MarketRank™: Gossamer Bio scored higher than 84% of companies evaluated by MarketBeat, and ranked 166th out of 956 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingGossamer Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageGossamer Bio has only been the subject of 1 research reports in the past 90 days.Read more about Gossamer Bio's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Gossamer Bio are expected to decrease in the coming year, from ($0.28) to ($0.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Gossamer Bio is -2.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Gossamer Bio is -2.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGossamer Bio has a P/B Ratio of 2.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Gossamer Bio's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.78% of the outstanding shares of Gossamer Bio have been sold short.Short Interest Ratio / Days to CoverGossamer Bio has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Gossamer Bio has recently decreased by 9.35%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGossamer Bio does not currently pay a dividend.Dividend GrowthGossamer Bio does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.67 Percentage of Shares Shorted2.78% of the outstanding shares of Gossamer Bio have been sold short.Short Interest Ratio / Days to CoverGossamer Bio has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Gossamer Bio has recently decreased by 9.35%, indicating that investor sentiment is improving significantly. News and Social Media2.0 / 5News SentimentN/A News SentimentGossamer Bio has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.Search Interest9 people have searched for GOSS on MarketBeat in the last 30 days. This is an increase of 800% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Gossamer Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Gossamer Bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.00% of the stock of Gossamer Bio is held by insiders.Percentage Held by Institutions81.23% of the stock of Gossamer Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Gossamer Bio's insider trading history. Receive GOSS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gossamer Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address GOSS Stock News HeadlinesGossamer Bio FY2024 EPS Estimate Raised by Leerink PartnrsNovember 15, 2024 | americanbankingnews.comGossamer Bio’s Strategic Advancements and Financial Resilience Support Buy RatingNovember 13, 2024 | markets.businessinsider.com[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.November 24, 2024 | Crypto Swap Profits (Ad)Gossamer Bio (GOSS) Gets a Buy from OppenheimerNovember 13, 2024 | markets.businessinsider.comIndustry Analysts Just Made A Sizeable Upgrade To Their Gossamer Bio, Inc. (NASDAQ:GOSS) Revenue ForecastsNovember 12, 2024 | finance.yahoo.comGossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)November 11, 2024 | businesswire.comGossamer Bio, Inc. (NASDAQ:GOSS) Just Reported And Analysts Have Been Lifting Their Price TargetsNovember 11, 2024 | finance.yahoo.comPromising Progress and Expansion Potential of Gossamer Bio’s Seralutinib Drive Buy RatingNovember 11, 2024 | markets.businessinsider.comSee More Headlines GOSS Stock Analysis - Frequently Asked Questions How have GOSS shares performed this year? Gossamer Bio's stock was trading at $0.9125 on January 1st, 2024. Since then, GOSS shares have decreased by 23.8% and is now trading at $0.6956. View the best growth stocks for 2024 here. How were Gossamer Bio's earnings last quarter? Gossamer Bio, Inc. (NASDAQ:GOSS) released its quarterly earnings data on Thursday, November, 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.18) by $0.04. The business earned $9.48 million during the quarter, compared to the consensus estimate of $4.52 million. When did Gossamer Bio IPO? Gossamer Bio (GOSS) raised $230 million in an initial public offering on Friday, February 8th 2019. The company issued 14,400,000 shares at a price of $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI served as the underwriters for the IPO. Who are Gossamer Bio's major shareholders? Top institutional investors of Gossamer Bio include Geode Capital Management LLC (0.98%), Jacobs Levy Equity Management Inc. (0.83%), Charles Schwab Investment Management Inc. (0.54%) and The Manufacturers Life Insurance Company (0.17%). Insiders that own company stock include Faheem Hasnain, Richard Aranda, Bryan Giraudo, Laura Carter and Caryn Peterson. View institutional ownership trends. How do I buy shares of Gossamer Bio? Shares of GOSS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Gossamer Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Gossamer Bio investors own include Voyager Therapeutics (VYGR), Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), The RMR Group (RMR), AUO (AUOTY) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings11/07/2024Today11/24/2024Fiscal Year End12/31/2024Next Earnings (Estimated)3/04/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GOSS CUSIPN/A CIK1728117 Webwww.gossamerbio.com Phone(858) 684-1300FaxN/AEmployees180Year FoundedN/APrice Target and Rating Average Stock Price Target$9.20 High Stock Price Target$15.00 Low Stock Price Target$4.00 Potential Upside/Downside+1,222.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-179,820,000.00 Net MarginsN/A Pretax Margin-64.89% Return on Equity-127.28% Return on Assets-22.12% Debt Debt-to-Equity Ratio3.64 Current Ratio6.74 Quick Ratio6.74 Sales & Book Value Annual Sales$105.32 million Price / Sales1.50 Cash FlowN/A Price / Cash FlowN/A Book Value$0.24 per share Price / Book2.90Miscellaneous Outstanding Shares226,604,000Free Float215,274,000Market Cap$157.63 million OptionableOptionable Beta1.96 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report This page (NASDAQ:GOSS) was last updated on 11/24/2024 by MarketBeat.com Staff From Our Partners[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredFirst JFK… next Elon?Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. ...Porter & Company | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredPopular Stocks at Risk Under Trump—Are You Holding These?The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely ...StockEarnings | SponsoredAre Your Retirement Savings Really Safe?What They Don’t Want You to Know About Your 401(k)The 2008-2010 crisis wiped out almost 50% of the value of retirement funds. If you knew it was coming, wouldn'...American Hartford Gold | SponsoredDonald Trump can’t save you from this crisisElon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force...Wide Moat Research | Sponsored#1 Crypto of 2024Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe Biggest Post-Election Market Shift Ever?Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gossamer Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gossamer Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.